drugset
drugset / Trial / NCT00003786

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00003786 ↗

Phase 2 Withdrawn University of Chicago National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with metastatic or recurrent colorectal cancer.

Timeline

Start
1999-04
Primary completion
2000-11
Completion
2000-11

Drugs

EvaluationDrugModalityDoseRoute
Subject irofulven Small molecule 11 mg/m2 Intravenous

Indications

colorectal cancer